Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Free Cash Flow for the year ending December 31, 2023: USD -62.84 M

Monte Rosa Therapeutics Inc Free Cash Flow is USD -62.84 M for the year ending December 31, 2023, a 40.36% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.

Monte Rosa Therapeutics Inc Free Cash Flow for the year ending December 31, 2022 was USD -105.38 M, a -52.51% change year over year.
Monte Rosa Therapeutics Inc Free Cash Flow for the year ending December 31, 2021 was USD -69.09 M, a -161.31% change year over year.
Monte Rosa Therapeutics Inc Free Cash Flow for the year ending December 31, 2020 was USD -26.44 M, a -249.85% change year over year.
Monte Rosa Therapeutics Inc Free Cash Flow for the year ending December 31, 2019 was USD -7.56 M.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends